Pramlintide: profile of an amylin analog

References

• Lebovitz HE. Adjunct therapy for Type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6(6), 326–334 (2010).
   PubMed Web of Science ®Google Scholar
• Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin. Pharmacother. 12(9), 1439–1451 (2011).
   PubMed Web of Science ®Google Scholar
• Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with Type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 13(2), 169–180 (2011).
   PubMed Web of Science ®Google Scholar
• Moore CX, Cooper GJ. Co-secretion of amylin and insulin from cultured islet β-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. 179(1), 1–9 (1991).
   PubMed Web of Science ®Google Scholar
• Hartter E, Svoboda T, Ludvik B et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34(1), 52–54 (1991).
   PubMed Web of Science ®Google Scholar
• Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol. Pharmacol. 44(3), 493–497 (1993).
   PubMed Web of Science ®Google Scholar
• Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch. Neurol. 66(3), 306–310 (2009).
   PubMedGoogle Scholar
• Riediger T, Zuend D, Becskei C, Lutz TA. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286(1), R114–R122 (2004).
   Google Scholar
• Lutz TA, Senn M, Althaus J, Del Prete E, Ehrensperger F, Scharrer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19(2), 309–317 (1998).
   PubMed Web of Science ®Google Scholar
• Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord. 25(7), 1005–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Jodka C, Green D, Young A, Gedulin B. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve (abstract). Diabetes 45, 235A (1996).
   Web of Science ®Google Scholar
• Gedulin BR, Jodka CM, Hermann K, Young AA. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC 187. Regul. Pept. 137, 121–127 (2006).
   PubMedGoogle Scholar
• Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53(Suppl. 3), S233–S238 (2004).
   PubMed Web of Science ®Google Scholar
• Colburn WA, Gottlieb AB, Koda J, Kolterman OG. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J. Clin. Pharmacol. 36(1), 13–24 (1996).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 14(4), 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153(2), 647–658 (2012).
   PubMed Web of Science ®Google Scholar
• Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with Type 2 diabetes. Diabetologia 48(5), 838–848 (2005).
   PubMed Web of Science ®Google Scholar
• Kong MF, King P, Macdonald IA et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40(1), 82–88 (1997).
   PubMed Web of Science ®Google Scholar
• Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human analog, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes. Horm. Metab. Res. 34, 504–508 (2002).
   PubMed Web of Science ®Google Scholar
• Fineman MS, Koda JE, Shen LZ et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with Type 1 diabetes. Metab. Clin. Exp. 51(5), 636–641 (2002).
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in Type 1 diabetes. Diabetes Care 25(4), 724–730 (2002).
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21(11), 1204–1212 (2004).
   PubMed Web of Science ®Google Scholar
• Edelman S, Garg S, Frias J et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in Type 1 diabetes. Diabetes Care 29(10), 2189–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Weyer C, Gottlieb A, Kim DD et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with Type 1 diabetes. Diabetes Care 26, 3074–3079 (2003).
   PubMed Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26(3), 784–790 (2003).
   PubMed Web of Science ®Google Scholar
• Merritt D, Schreiner B, Harris S, DeYoung MB, Strobel S, Lauinger J. Dose accuracy and injection force of disposable pens delivering pramlintide for the treatment of diabetes. J. Diabetes Sci. Technol. 4(6), 1438–1446 (2010).
   Google Scholar
• Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with Type 1 diabetes: observations from a pilot study. Endocr. Pract. 15(7), 689–695 (2009).
   PubMed Web of Science ®Google Scholar
• Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four-hour simultaneous subcutaneous basal-bolus administration of insulin and amylin in adolescents with Type 1 diabetes decreases postprandial hyperglycemia. J. Clin. Endocrinol. Metab. 94(5), 1608–1611 (2009).
   PubMed Web of Science ®Google Scholar
• King AB. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated Type 1 diabetes patients. Diabetes Technol. Ther. 12(2), 105–108 (2010).
   PubMed Web of Science ®Google Scholar
• Pencek R, Roddy T, Peters Y et al. Safety of pramlintide added to mealtime insulin in patients with Type 1 or Type 2 diabetes: a large observational study. Diabetes Obes. Metab. 12(6), 548–551 (2010).
   Google Scholar
• Chase HP, Lutz K, Pencek R, Zhang B, Porter L. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with Type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J. Pediatr. 155(3), 369–373 (2009).
   PubMed Web of Science ®Google Scholar
• Kishiyama CM, Burdick PL, Cobry EC et al. A pilot trial of pramlintide home usage in adolescents with Type 1 diabetes. Pediatrics 124(5), 1344–1347 (2009).
   Google Scholar
• Fennoy I. Pramlintide in pediatric Type 1 diabetes. J. Pediatr. 155(3), 308–309 (2009).
   Google Scholar
• Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 32(8), 1411–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. Diabetes Educ. 35(1), 136–146 (2009).
   PubMed Web of Science ®Google Scholar
• Marrero DG, Crean J, Zhang B et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with Type 1 diabetes. Diabetes Care 30(2), 210–216 (2007).
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Polonsky WH, Best JH. Patient reported outcomes in adults with Type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr. Med. Res. Opin. 26(5), 1047–1054 (2010).
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr, Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56(Suppl. 1), 122–132 (2009).
   PubMed Web of Science ®Google Scholar
• Lush CW, Darsow T, Zhang B, Lorenzi G, Frias JP. Pramlintide as an adjunct to basal insulin: effects on glycemic control and weight in patients with Type 2 diabetes. Insulin 2, 166–172 (2007).
   Google Scholar
• Riddle M, Frias J, Zhang B et al. Pramlintide improved glycemic control and reduced weight in patients with Type 2 diabetes using basal insulin. Diabetes Care 30(11), 2794–2799 (2007).
   PubMed Web of Science ®Google Scholar
• Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with Type 2 diabetes. Diabetes Care 32(9), 1577–1582 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman I, Parker B, Doran S et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity (Silver Spring) 15(5), 1179–1186 (2007).
   PubMedGoogle Scholar
• Smith SR, Blundell JE, Burns C et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am. J. Physiol. Endocrinol. Metab. 293(2), E620–E627 (2007).
   PubMed Web of Science ®Google Scholar
• Aronne L, Fujioka K, Aroda V et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a Phase 2, randomized, placebo-controlled, dose-escalation study. J. Clin. Endocrinol. Metab. 92(8), 2977–2983 (2007).
   PubMed Web of Science ®Google Scholar
• Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31(9), 1816–1823 (2008).
   PubMed Web of Science ®Google Scholar
• Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann. Pharmacother. 44(3), 538–545 (2010).
   Google Scholar
• Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J. Clin. Endocrinol. Metab. 95(5), 2367–2375 (2010).
   PubMed Web of Science ®Google Scholar
• Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36(9), 857–862 (1993).
   PubMed Web of Science ®Google Scholar
• Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 36(12), 2220–2228 (1995).
   PubMed Web of Science ®Google Scholar
• Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am. J. Physiol. Gastrointest. Liver Physiol. 278(6), G946–G951 (2000).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Albrecht M, Linke R et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with Type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care 31(12), 2325–2331 (2008).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Albrecht M, Linke R et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am. J. Physiol. Endocrinol. Metab. 294(1), E103–E109 (2008).
   PubMed Web of Science ®Google Scholar
• Levetan C, Want LL, Weyer C et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with Type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26(1), 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in Type 1 diabetes. Diabetes Technol. Ther. 10(5), 391–396 (2008).
   Google Scholar